Orexigen's (NASDAQ:OREX) news this week wasn't all bad -- after all, it looks like drug Contrave is a good bet for approval, the market's unhappiness about the FDA's delayed PDUFA date notwithstanding.

The delay in potential approval was tied to the need to find an agreement about post-marketing requirements. That seems to imply that the drug will be...approved to be marketed. Nonetheless, given the commercialization troubles competitors Arena Pharmaceuticals (NASDAQ:ARNA) and VIVUS (NASDAQ:VVUS) have had, some caution is appropriate when considering potential sales.

In this week's health care-focused episode of Where The Money Is, health care analysts Michael Douglass and David Williamson lay out why they still prefer to wait on the sidelines.